Previous 10 | Next 10 |
home / stock / lmllf / lmllf news
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University in support of forthc...
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substance Clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in second half of September 2022 Genvion Corporation formall...
Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" Pharmadrug " or the " Company "), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities o...
PharmaDrug ( OTCQB:LMLLF ) has raised $650,000 through the sale of debenture units. Each unit is comprised of a $1,000 principal amount convertible secured debenture and 20,000 common share purchase warrants. Each debenture bears interest at a rate of 15% per annum payable...
Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelic...
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NAS...
Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049) Dose range finding demonstrates that oral cepharanthine-alone was ...
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutic...
Khiron Life Sciences (OTCQX:KHRNF +10.2%) has entered into an agreement to acquire Pharmadrug GmbH from its parent PharmaDrug (OTCPK:LMLLF +7.1%). The acquisition will provide Khiron with an EU GMP-certified European manufacturing and distribution hub for various pharmaceutical prod...
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) (" Khiron ") to sell all of the outstand...
News, Short Squeeze, Breakout and More Instantly...
2024-05-23 11:51:50 ET This company believes that the only viable way to produce a safe supply of street drugs is to develop biosynthetic versions of these substances to be manufactured domestically in a regulated %Pharmaceutical supply chain. The signing of a recent LOI could potential...
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved...
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent ...